CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) has secured registration of five trademarks from the Canadian Intellectual Property Office, marking a step forward in strengthening its global intellectual property and branding strategy.
The newly registered trademarks include the company’s house marks, “Enveric” and “Enveric Biosciences,” along with two “Plus Marks” used in product packaging designs and the phrase “Next Generation Mental Health.”
“The registration of a Company’s house marks, such as our marks Enveric and Enveric Biosciences, is an important intellectual property milestone supporting our branding strategies for our future products. We thank the Canadian Intellectual Property Office for its recent action,” said Joseph Tucker, Ph.D., CEO of Enveric.
The additional trademarks are intended to support branding tied to the company’s pipeline of neuroplastogenic small-molecule therapeutics aimed at treating psychiatric and neurological disorders.
“These additional marks reflect the Company’s view of the expected positive impact of its pipeline products under development on mental health, including the lead molecule EB-003, for which an IND filing with the FDA is planned in 2026,” Tucker added.
The company noted that its house marks are already registered in the United States, Europe, and the U.K., and that the Canadian registrations further reinforce its branding strategy across key international markets as it advances development of EB-003 and other programs.
